AGTC:NSD-Applied Genetic Technologies Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.74

Change

0.00 (0.00)%

Market Cap

USD 0.16B

Volume

0.63M

Avg Analyst Target

USD 21.00 (+461.50%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.

Company Website : http://www.agtc.com

Address : 14193 NW 119th Terrace, Alachua, FL, United States, 32615

Employees : 83

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 2.19

52 Week High : 9.67

Short Ratio : 2.14

52 Week Low : 3.47

Shorted Shares : 3,861,575

200 Day Moving Average : 4.57

Shorted Shares Previous Month : 5,325,884

50 Day Moving Average : 4.03

Shares Held By Insiders : 0.72%

Short Percentage : 9.00%

Shares Held by Institutions : 57.58%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

 USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

 USD29.28B N/A N/A
GMAB Genmab A/S

N/A

 USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

 USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

 USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD21.44B N/A N/A

ETFs Containing AGTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.56% 56% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.56% 55% F 24% F
Trailing 12 Months  
Capital Gain -35.74% 27% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.74% 27% F 9% F
Trailing 5 Years  
Capital Gain -75.36% 25% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.36% 25% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -0.49% 32% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.49% 32% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 49.42% 64% D 36% F
Risk Adjusted Return -1.00% 32% F 21% F
Market Capitalization 0.16B 31% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.38 23% F 29% F
Price/Book Ratio 1.73 81% B- 67% D+
Price / Cash Flow Ratio -3.84 31% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -66.21% 42% F 25% F
Return on Invested Capital -59.00% 41% F 14% F
Return on Assets -31.54% 33% F 10% F
Debt to Equity Ratio 13.63% 51% F 67% D+
Technical Ratios  
Short Ratio 2.14 64% D 54% F
Short Percent 10.00% 29% F 19% F
Beta 2.19 15% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector